Actions of cannabinoid receptor ligands on rat cultured sensory neurones: implications for antinociception. 2001

R A Ross, and A A Coutts, and S M McFarlane, and S Anavi-Goffer, and A J Irving, and R G Pertwee, and D J MacEwan, and R H Scott
Department of Biomedical Sciences, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK. r.ross@abdn.ac.uk

Cannabinoids modulate nociceptive processing in models of acute, inflammatory and neuropathic pain. We have investigated the location and function of cannabinoid receptors on cultured neonatal dorsal root ganglion (DRG) neurones and F-11 cells, a dorsal root ganglionxneuroblastoma hybridoma which displays several of the features of authentic DRG neurones. CB(1) receptor immunolabelling was observed on the cell bodies and as fine puncta on processes of both cultured DRG neurones and F-11 cells. Additionally, fluorescence-activated cell sorting (FACS) analysis provided evidence that both CB(1) and CB(2) receptors are expressed on populations of cells within the cultured DRG and F-11 cells. The cannabinoid receptor agonist (+)-WIN55212 (10 and 100 nM) inhibited the mean voltage-activated Ca(2+) current in DRG neurones by 21% and 30%, respectively. The isomer, (-)-WIN55212 (10 and 100 nM) produced significantly less inhibition of 6% and 10% respectively. The CB(1) selective receptor antagonist SR141716A (100 nM) enhanced the peak high voltage-activated Ca(2+) current by 24% and simultaneous application of SR141716A (100 nM) and (+)-WIN55212 (100 nM) resulted in a significant attenuation of the inhibition obtained with (+)-WIN55212 alone. These data give functional evidence for the hypothesis that the analgesic actions of cannabinoids may be mediated by presynaptic inhibition of transmitter release in sensory neurones.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008024 Ligands A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed) Ligand
D009025 Morpholines Tetrahydro-1,4-Oxazines,Tetrahydro 1,4 Oxazines
D009281 Naphthalenes Two-ring crystalline hydrocarbons isolated from coal tar. They are used as intermediates in chemical synthesis, as insect repellents, fungicides, lubricants, preservatives, and, formerly, as topical antiseptics.
D009475 Neurons, Afferent Neurons which conduct NERVE IMPULSES to the CENTRAL NERVOUS SYSTEM. Afferent Neurons,Afferent Neuron,Neuron, Afferent
D011955 Receptors, Drug Proteins that bind specific drugs with high affinity and trigger intracellular changes influencing the behavior of cells. Drug receptors are generally thought to be receptors for some endogenous substance not otherwise specified. Drug Receptors,Drug Receptor,Receptor, Drug
D002121 Calcium Channel Blockers A class of drugs that act by selective inhibition of calcium influx through cellular membranes. Calcium Antagonists, Exogenous,Calcium Blockaders, Exogenous,Calcium Channel Antagonist,Calcium Channel Blocker,Calcium Channel Blocking Drug,Calcium Inhibitors, Exogenous,Channel Blockers, Calcium,Exogenous Calcium Blockader,Exogenous Calcium Inhibitor,Calcium Channel Antagonists,Calcium Channel Blocking Drugs,Exogenous Calcium Antagonists,Exogenous Calcium Blockaders,Exogenous Calcium Inhibitors,Antagonist, Calcium Channel,Antagonists, Calcium Channel,Antagonists, Exogenous Calcium,Blockader, Exogenous Calcium,Blocker, Calcium Channel,Blockers, Calcium Channel,Calcium Blockader, Exogenous,Calcium Inhibitor, Exogenous,Channel Antagonist, Calcium,Channel Blocker, Calcium,Inhibitor, Exogenous Calcium
D002186 Cannabinoids Compounds having the cannabinoid structure. They were originally extracted from Cannabis sativa L. The most pharmacologically active constituents are TETRAHYDROCANNABINOL; CANNABINOL; and CANNABIDIOL. Cannabinoid
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D005453 Fluorescence The property of emitting radiation while being irradiated. The radiation emitted is usually of longer wavelength than that incident or absorbed, e.g., a substance can be irradiated with invisible radiation and emit visible light. X-ray fluorescence is used in diagnosis.

Related Publications

R A Ross, and A A Coutts, and S M McFarlane, and S Anavi-Goffer, and A J Irving, and R G Pertwee, and D J MacEwan, and R H Scott
April 2004, British journal of pharmacology,
R A Ross, and A A Coutts, and S M McFarlane, and S Anavi-Goffer, and A J Irving, and R G Pertwee, and D J MacEwan, and R H Scott
January 2010, Neuroscience letters,
R A Ross, and A A Coutts, and S M McFarlane, and S Anavi-Goffer, and A J Irving, and R G Pertwee, and D J MacEwan, and R H Scott
October 1998, British journal of pharmacology,
R A Ross, and A A Coutts, and S M McFarlane, and S Anavi-Goffer, and A J Irving, and R G Pertwee, and D J MacEwan, and R H Scott
January 1988, Physiologia Bohemoslovaca,
R A Ross, and A A Coutts, and S M McFarlane, and S Anavi-Goffer, and A J Irving, and R G Pertwee, and D J MacEwan, and R H Scott
June 1989, The Journal of physiology,
R A Ross, and A A Coutts, and S M McFarlane, and S Anavi-Goffer, and A J Irving, and R G Pertwee, and D J MacEwan, and R H Scott
January 1998, Neuroscience letters,
R A Ross, and A A Coutts, and S M McFarlane, and S Anavi-Goffer, and A J Irving, and R G Pertwee, and D J MacEwan, and R H Scott
August 1992, British journal of pharmacology,
R A Ross, and A A Coutts, and S M McFarlane, and S Anavi-Goffer, and A J Irving, and R G Pertwee, and D J MacEwan, and R H Scott
May 2006, Pain,
R A Ross, and A A Coutts, and S M McFarlane, and S Anavi-Goffer, and A J Irving, and R G Pertwee, and D J MacEwan, and R H Scott
December 1988, British journal of pharmacology,
R A Ross, and A A Coutts, and S M McFarlane, and S Anavi-Goffer, and A J Irving, and R G Pertwee, and D J MacEwan, and R H Scott
September 2001, Pain,
Copied contents to your clipboard!